Diprospan is a drug intended for systemic use.
Release form and composition
Diprospan is released as a yellow transparent slightly viscous suspension, in 1 ml glass ampoules.
One ml of the product contains 2.63 mg of betamethasone sodium phosphate, 6.43 mg of betamethasone dipropionate and such excipients as:
- Water for injections;
- Sodium hydrophosphate dihydrate;
- Sodium chloride;
- Benzyl alcohol;
- Polysorbate 80;
- Disodium edetate;
- Methyl parahydroxybenzoate;
- Carmellose sodium;
- Propyl parahydroxybenzoate;
- Hydrochloric acid.
Indications for use
Diprospan prescribed in cases of:
- Allergic diseases;
- Diseases of the musculoskeletal system and soft tissues;
- Dermatological diseases;
- Primary or secondary adrenal insufficiency;
- Systemic diseases of the connective tissue.
Diprospan is also prescribed for the treatment of other diseases and pathological conditions requiring therapy with systemic glucocorticosteroids.
Application Diprospana contraindicated in case of hypersensitivity to the active and auxiliary components in its composition, as well as in the following cases:
- Systemic mycosis;
- Infectious arthritis;
- Unstable joint;
- Intervertebral space insertions or infected surfaces.
With caution, the drug is prescribed to patients with liver cirrhosis, ulcerative colitis, hypothyroidism, diverticulitis, gastric ulcer and duodenal ulcer, osteoporosis, severe myasthenia, renal failure, thrombocytopenic purpura and arterial hypertension.
During pregnancy and during the breastfeeding period, the use of the drug is permissible only in cases where the expected effect of the therapy significantly exceeds the possible risk to the developing fetus or infant.
Dosing and Administration
The suspension is administered intramuscularly, periarticular, intraarticular, intracutaneous, intrabursal, intrafocal or intratissue.
The route of administration and the dosage regimen of Diprospan is set individually, depending on the severity of the disease, indications and the patient's response to treatment.
In cases of systemic use of the drug, the initial dose is on average 1-2 ml.
The instructions to Diprospan indicated that the drug may cause side effects from certain organs and body systems, namely:
- Hypernatremia, weight gain and excretion of potassium, hypokalemic alkalosis, increased calcium excretion, lipomatosis, fluid retention in tissues and a negative nitrogen balance (metabolism);
- Chronic heart failure and high blood pressure (cardiovascular system);
- Posterior subcapsular cataract, blindness, increased intraocular pressure, exophthalmos and glaucoma (organ of vision);
- Erosive and ulcerative lesions of the digestive tract, pancreatitis, hiccups and flatulence (digestive system);
- Spasms, insomnia, dizziness, mood changes, headache, euphoria, depression and personality disorders (central and peripheral nervous system).
Diprospan causes side effects from the endocrine and musculoskeletal systems, namely:
- Disruption of the menstrual cycle, secondary adrenal insufficiency, Itsenko-Cushing syndrome, steroid diabetes mellitus, growth retardation and sexual development in children, reduction of carbohydrate tolerance and impaired intrauterine development;
- Muscle weakness, joint instability, steroid myopathy, pathological fractures of the tubular bones, loss of muscle mass, tendon ruptures, increased myasthenic symptoms, compression fracture of the spine and osteoporosis.
Diprospan can also cause dermatological, allergic and other reactions, namely:
- Impaired wound healing, petechiae, atrophy and thinning of the skin, increased sweating, ecchymosis, dermatitis, a tendency to the development of pyoderma and candidiasis, steroid acne and striae;
- Anaphylactic reactions, angioedema, shock, and hypotension;
- Blood rush after injection and neurogenic arthropathy.
Against the background of Diprospan's use, patients with a tendency to psychosis or emotional instability may experience mental disorders.
It is important to warn patients receiving the drug in doses that suppress immunity about the need to avoid contact with measles or chicken pox.
The use of the drug in active tuberculosis is permissible only in cases of disseminated or fulminant tuberculosis in combination with adequate anti-tuberculosis therapy.
Patients during drug therapy should refrain from conducting potentially hazardous activities that require increased attention and speed of psychomotor reactions.
If the duration of Diprospan therapy is six months or more, it is recommended to periodically conduct an ophthalmologic examination.
It is necessary to control the water-electrolyte balance with simultaneous use of the drug with cardiac glycosides or drugs that affect the electrolyte composition of the plasma.
When hypoprothrombinemia Diprospan carefully prescribed in combination with acetylsalicylic acid.
Synonymous with the drug are Floterone and Betamethasone. The analogues of Diprospan include Megadeksan, Ivepred, Hydrocortisone, Solu-Cortef, Deperzolone, Lemod, Cortisone, Kenalog, Rectodelt, Medopred, Triamcinolone, Prednisolone and Metipred.
Terms and conditions of storage
The instructions to Diprospan indicated that the drug should be stored in a dark, dry and inaccessible to children place, at a temperature varying between 15-25 ºС.
From pharmacies, the drug is released on prescription. The shelf life of the suspension, subject to the basic recommendations of the manufacturer, is two years.